Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Possible etiology of improvements in both quality of life and overlapping gastroesophageal reflux disease by proton pump inhibitor treatment in a prospective randomized controlled trial
BMC Gastroenterology, Volume 13, No. 1, Article 145, Year 2013
Notification
URL copied to clipboard!
Description
Background: Symptoms suggestive of functional dyspepsia (FD) and irritable bowel syndrome (IBS) frequently overlap with those of gastroesophageal reflux disease. Despite the high prevalence of symptomatic overlap, the underlying etiology remains poorly defined. We assessed the correlation of symptomatic relief and health-related quality of life (HRQoL) with healing of reflux esophagitis to further derive insights into the underlying etiology.Methods: 626 patients with reflux esophagitis were enrolled into one of two treatment groups (classical healing concept or the complete remission concept) to investigate differences in treatment intensity. Patients were treated with pantoprazole until esophageal mucosal healing. Remission was followed for up to 6 months without treatment. Gastro-intestinal symptoms and HRQoL were analyzed using disease-specific, psychometrically validated patient-reported outcome instruments (ReQuest™, GERDyzer™).Results: Symptomatic burden reflected by ReQuest™ substantially decreased from baseline to end of treatment by 83% and 88% in either treatment group, respectively. ReQuest™ scores significantly decreased in patients with or without heartburn and in those with symptoms suggestive of FD and IBS, indicating response of all symptom categories to treatment (p < 0.005). Therapy-associated relief of symptoms was paralleled by substantial gains in HRQoL, which continued to stabilize post-treatment.Conclusions: Pantoprazole is effective in relieving upper and lower gastro-intestinal symptoms overlapping with erosive esophagitis, and provides sustained improvement in HRQoL post-treatment. Our results propose a link between both healing of erosive esophagitis and the slower remission of upper and lower gastro-intestinal symptoms. Since the improvement observed is likely to be multifactorial, the possibility for an immune-mediated etiology and identification of putative susceptibility factors by genome-wide association study may provide focus for future research. Trial registration: ClinicalTrials.gov identifier: NCT00325676. © 2013 Mönnikes et al.; licensee BioMed Central Ltd.
Authors & Co-Authors
Mönnikes, H.
Germany, Berlin
Charité – Universitätsmedizin Berlin
Schwan, T.
Germany, Konstanz
Nycomed: a Takeda Company
van Rensburg, Christoffel Johannes
South Africa, Tygerberg
Tygerberg Hospital
Straszak, A.
Poland, Poznan
City Hospital
Theek, C.
Germany, Essen
Pierrel Research
Lühmann, R.
Germany, Konstanz
Nycomed: a Takeda Company
Sander, P.
Germany, Konstanz
Nycomed: a Takeda Company
Tholen, Anne
Switzerland, Zurich
Takeda Pharma ag
Statistics
Citations: 8
Authors: 8
Affiliations: 6
Identifiers
Doi:
10.1186/1471-230X-13-145
e-ISSN:
1471230X
Research Areas
Disability
Health System And Policy
Study Design
Cross Sectional Study
Cohort Study
Study Approach
Quantitative